Impa Pharma-B (07630.HK) proposes the adoption of a share award scheme.

Gelonghui, July 10 — Impharma-B (07630.HK) announced that, upon the recommendation of the Board’s Remuneration Committee, the Board has resolved to propose the adoption of a share award plan. The maximum number of H-shares that may be awarded under the share award plan shall not exceed 5.0% of the total number of issued shares of the Company (excluding treasury shares) as of the adoption date (the "Plan Authorization Limit"). For the purpose of calculating the Plan Authorization Limit, lapsed or cancelled awards shall not be counted as utilized. The objectives and purposes of the share award plan are to recognize the contributions made by eligible participants to the Group, align their interests with those of the Company and its shareholders, and provide them with

Gelonghui FinanceJul 10 21:29

InnoCare Pharma-B (07630.HK) received an increase of 350,000 H-shares from Tencent Holdings Limited, valued at approximately HK$12.6602 million.

As reported on July 6, according to a filing disclosed by the Hong Kong Stock Exchange on July 6, Tencent Holdings Limited acquired an additional 350,000 H-shares of ImpACT Therapeutics-B (07630.HK) on June 30 at an average price of HK$36.1719 per share, for a total value of approximately HK$12.6602 million. Following this acquisition, Tencent Holdings Limited’s latest shareholding stands at 19,880,500 shares, increasing its long position stake from 6.91% to 7.04%. Source: HKEX Equity Disclosure – What is equity disclosure?

Futu NewsJul 6 17:12

Biopharmaceuticals: Innovation-driven industry trends are clear, with international expansion and commercial insurance offering breakthrough opportunities.

In the short term, healthcare cost containment and anti-corruption efforts in the medical sector have exerted some impact on healthcare demand, while innovative payment models, commercial insurance formularies, and off-hospital care settings may drive industry improvements. Although geopolitical tensions and shifts in liquidity have triggered a temporary pullback in the innovative drug sector and related industries, the long-term trends of innovation and international expansion remain clear, and the current correction presents medium- to long-term investment opportunities. In the second half of 2026, we continue to recommend a barbell strategy: one end focused on innovation and internationalization opportunities, and the other anchored by traditional, stable dividend-paying assets. The development trajectory of the innovative drug industry chain is clear, and order trends in the pharmaceutical supply chain remain robust. Despite short-term pressures on the innovative drug sector stemming from macroeconomic co

CICC InsightsJul 1 10:08

Impa Pharmaceuticals-B received a share purchase of 20,000 shares from shareholder Shi Yi at an average price of approximately HK$35.94 per share.

According to the latest data from the Hong Kong Stock Exchange, on June 24, shareholder Shi Yi acquired an additional 20,000 shares of ImpACT Pharmaceuticals-B (07630.HK) at HK$35.9388 per share, for a total consideration of approximately HK$718,800. Following this transaction, his latest shareholding stands at approximately 39,551,500 shares, representing a stake of 14.00%.

Sina HK StocksJun 30 08:29

IMPACT Therapeutics Wins Strong Shareholder Backing for AGM Resolutions and Capital Mandates

TipRanksJun 25 22:40

IMPACT Therapeutics, Inc. Class H (7630) Has a New Rating From Goldman Sachs

TipRanksJun 18 16:05 · Ratings